The Regenesis Project

Home » The Regenesis Project

Clinical Research

We are actively engaged in numerous clinical research studies that give patients access to cutting edge therapeutic modalities including focused ultrasound, TMS, and light therapy. Our ongoing clinical trials cover conditions such as dementia, Parkinson’s disease, traumatic brain injury, anxiety, depression, and OCD as well as chronic pain and coma.

Current Research Studies:

1. Open–Label Study for the Use of Transcranial Ultrasound Treatment

Conditions:Depression, Anxiety, ADHD, Parkinson’s,Neuropathic Pain, Neurodegenerative Dementias

Various ongoing clinical trials involving condition-specific protocols to evaluate the potential effectiveness of focused ultrasound as a therapeutic intervention. This non-invasive, targeted technology uses ultrasonic energy to stimulate or inhibit deeper brain structures without incisions or radiation. Treatment time and target location vary depending on clinical indication.

2. Prodrome Neuro: An Open-Label Study of Omega–3 Oil Nutritional Supplementation for Aging-Related Cognitive Decline

Conditions:Memory impairment, aging related cognitive decline, Alzheimer’s disease, Parkinson’s disease, dementia

This clinical trial investigates the use of ProdromeNeuro, an Omega–3 nutritional supplement oil, among participants with aging-related cognitive decline. Research suggests that age-related cognitive changes may be affected by brain lipids and the health of cell membranes. The 100% vegan, all-natural, and pure synthetic Omega-3 plasmalogen precursor is specifically designed to elevate Omega-3 plasmalogens and help the body to restore, maintain, and optimize neural membranes.It is hoped that the consumption of this product over the course of the study will yield improved plasmalogen levels as well as optimized memory function among older adults. For more information on ProdromeNeuro check out our latest press release hereand visit https://prodromesciences.com/

3. The Treatment of Dementia with Bosutinib: an Open-Label Study of a Tyrosine Kinase Inhibitor

Conditions: Memory impairment, Alzheimer’s disease, Parkinson’s disease, dementia

For patients suffering from Alzheimer’s and Parkinson’s conditions, no therapy has been proven to halt or reverse the progressive neurological deterioration. The pursuit of an effective therapeutic intervention has inspired interest in tyrosine kinase inhibitors (TKIs) such as bosutinib. Our ongoing expanded phase I clinical trial studies the use of bosutinib for the investigational treatment of degenerative dementias.

Click here to see our report presented to Pfizer demonstrating unexpected early results that show a marked improvement in functional scores among participants with Parkinson’s and Alzheimer’s diseases.

4. The Use of Transcranial Near-Infrared Laser Stimulation

Conditions: Depression, Anxiety, Dementia, Traumatic Brain Injury

Near-infrared laser stimulation has garnered interest for a variety of cited benefits, some of which include cognitive enhancement, mood regulation, cellular recovery and mitochondrial repair. Our study investigates the use of transcranial near-infrared laser stimulation as a potential therapeutic modality for a variety of neurological conditions, including those listed above. Treatment duration and target areas depend on the clinical indication.